With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …

Until recently, the concept of antibodies as in vivo therapeutics was still considered to be an
exceedingly ambitious goal. However, in 2003, the situation has been completely …

Development trends for therapeutic antibody fragments | Nature Biotechnology Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

Multivalency is one of the hallmarks of antibodies, by which enormous gains in functional
affinity, and thereby improved performance in vivo and in a variety of in vitro assays are …

Engineered antibodies now represent over 30% of biopharmaceuticals in clinical trials, as
highlighted by recent approvals from the US Food and Drug Administration. Recombinant …

Recombinant antibodies and their fragments now represent over 30% of all biological
proteins undergoing clinical trials, which recently culminated in FDA approval for the first …

Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …

Antibodies are essential in modern life sciences biotechnology. Their architecture and
diversity allow for high specificity and affinity to a wide array of biochemicals. Combining …

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical
industry. There are currently 18 monoclonal antibodies in the market that have been …

Molecular engineering has contributed immensely to the clinical success of antibodies in
recent years. The modular structure of antibodies has permitted their modification in …